ID: ALA2409470

Max Phase: Preclinical

Molecular Formula: C21H22O6

Molecular Weight: 370.40

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCOc1cc(O)c2c(=O)cc(-c3ccc(O)c(O)c3)oc2c1

Standard InChI:  InChI=1S/C21H22O6/c1-2-3-4-5-8-26-14-10-17(24)21-18(25)12-19(27-20(21)11-14)13-6-7-15(22)16(23)9-13/h6-7,9-12,22-24H,2-5,8H2,1H3

Standard InChI Key:  OAVBFNPMFUTTAH-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 370.40

Molecular Weight (Monoisotopic): 370.1416

AlogP: 4.54

#Rotatable Bonds: 7

Polar Surface Area: 100.13

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.34

CX Basic pKa:

CX LogP: 4.76

CX LogD: 4.42

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.42

Np Likeness Score: 0.95

References

1. Wang QQ, Cheng N, Zheng XW, Peng SM, Zou XQ..  (2013)  Synthesis of organic nitrates of luteolin as a novel class of potent aldose reductase inhibitors.,  21  (14): [PMID:23683835] [10.1016/j.bmc.2013.04.066]

2. Yamauchi K, Fujieda A, Mitsunaga T..  (2018)  Selective synthesis of 7-O-substituted luteolin derivatives and their melanonenesis and proliferation inhibitory activity in B16 melanoma cells.,  28  (14): [PMID:29887353] [10.1016/j.bmcl.2018.05.051]

Source

Source(1):

• Scientific Literature